OBI Pharma Inc.: OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

Poster Presentations to highlight the latest research on OBI-999's (anti-Globo H ADC) synergistic anti-tumor effect in combination with pembrolizumab and OBI's development of CAR T-cell cancer immunotherapy

Related Keywords

United States ,Taiwan ,Taipei ,T Ai Pei ,Taiwanese ,American ,Jhih Jie Yang ,Chun Chung Wang ,Woan Eng Chan ,Chi Huan Lu ,Adagloxad Simolenin ,Jiann Shiun Lai ,American Association Of Cancer Research ,Pharma Inc ,Poster Presentations ,American Association ,Cancer Research ,Annual Meeting ,Scientific Officer Ming Tain Lai ,Globoh Expressing ,Tumor Stromal Cell ,Including Immune Cell ,Board Number ,Presentation Number ,Wednesday Apr ,Globoh Targeted ,Shiou Ling Jian ,Tuesday Apr ,Pharma ,Nnounces ,Poster ,Presentations ,Racr ,023 ,Nnual ,Meeting ,Combination ,Synergy ,Checkpoint ,Inhibitor ,Fell ,Globo ,Argeted ,Immunotherapy ,